Printer Friendly

Sun Pharma Receives USFDA Approvals for 4 Generic Products.

MUMBAI, India, January 7 /PRNewswire/ --

- Company Receives its First Controlled Substance Product Approval

Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE:SUNPHARMA, BSE: 524715) announced that together with its subsidiaries, it has received final approval from USFDA for several Abbreviated New Drug Applications (ANDA). Approval was received for generic hydocodone bitartate with acetaminophen (APAP) tablets. Approval was also received for generic Aredia(R), pamidronate disodium for injection USP, generic Lopid (R), gemfibrozil tablets, USP, and generic Phenargan(R), promethazine hydrochloride tablets.

First Controlled Substance approval

The approvals for Hydrocodone with APAP are the first approvals for products based on controlled substances.

Hydrocodone with APAP is a narcotic analgesic indicated in the treatment of relief of moderate to moderately severe pain of acute, chronic, or post-operative types. This is a Schedule III drug, regulated partly by the Controlled Substance Act of 1940 in the US.

Approvals have been received for ten generic versions of these tablets containing Hydrocodone and APAP in the following strengths; 5/325 mg, 7.5/325 mg, 10/325 mg, 5/500 mg, 7.5/500 mg, 10/500 mg, 7.5/650 mg, 10/650 mg, 10/660 mg and 7.5/750 mg.

 Hydrocodone + APAP Bioequivalent to
 strengths approved

 5/500 mg Vicodin 5 /500 mg tablets of Abbott Laboratories
 7.5/500 mg Hydrocodone with APAP 7.5 /500 mg tablets of Mikart
 Inc
 10/500 mg Lortab 10/500 mg of UCB Pharma, Inc.
 7.5/750 mg Vicodin ES tablets 7.5/ 750mg of Abbott Laboratories
 7.5/650 mg Hydrocodone with APAP tablets 7.5/650 mg of Mikart
 Inc.
 10/650 mg Hydrocodone with APAP 10 /650 mg tablets of Mikart
 Inc
 10/660 mg Hydrocodone with APAP 10/660 mg of Mallinckdrodt,
 Inc
 5/325 mg Norco tablets, Hydrocodone with APAP 5/325 mg, from
 Watson Laboratories
 7.5/325 mg Norco tablets, Hydrocodone with APAP 7.5/ 325 mg,
 from Watson Laboratories
 10/325 mg Norco tablets, Hydrocodone with APAP 10/325 mg, from
 Watson Laboratories



These strengths have annual sales of approximately USD 540 million in the US which includes branded as well as generic products.

Other approvals

Approval has also been received for generic Lopid(R) tablets. Generic Lopid contains gemfibrozil 600 mg, a cholesterol reducing agent and has annual sales of about USD 44 million in the US.

Approval for generic Aredia(R), pamidronate disodium for injection USP. Generic Aredia(R) is indicated in the treatment of hypercalcemia of malignancy, paget's disease, osteolytic bone metastases of breast cancer and osteolytic lesions of multiple myeloma.

Approval has been received for two strengths. 30 mg/ vial and 90 mg/ vial. Genericand branded Aredia(R) has sales of approximately USD 20 million in the US.

In addition, approval was received for generic Phenargan tablets. promethazine hydrochloride USP. Generic Phenargan is an antihistamine/ antiemetic and is available as 12.5 mg, 25 mg and 50 mg tablets bioequivalent to generic Promethazine hydrochloride from Sandoz, Inc. Generic Phenargan(R) has sales of approximately USD 50 million in the US.

These products, to be manufactured at multiple facilities of Sun Pharma (together with its subsidiaries) in India and US, will reach market shortly.

Vicodin (R) is a registered trademark of Abbott Laboratories.

Lopid(R) is a registered trademark of Pfizer Pharmaceuticals Ltd.

Aredia(R) is a registered trademark of Novartis Pharmaceutical Corporation

Phenargan(R) is a registered trademark of Wyeth Pharmaceuticals.

About Sun Pharmaceutical Industries Ltd.

Established in 1983, listed since 1994 and headquartered in India, Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE:SUNPHARMA, BSE: 524715) is an international, integrated, speciality pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in India, US and several other markets across the world. In India, the company is a leader in niche therapy areas of psychiatry, neurology, cardiology, diabetology, gastroenterology, and orthopedics. The company has strong skills in product development, process chemistry, and manufacturing of complex API, as well as dosage forms. More information about the company can be found at http://www.sunpharma.com.

Contacts: Uday Baldota, Tel: +91-22-6645-5645, Xtn 605, Tel: +91-22-66455605, Direct Mobile +91-98670-10529, E mail uday.baldota@sunpharma.com; Mira Desai, Tel: +91-22-6645-5645, Xtn 606, Tel: +91-22-66455606, Direct, Mobile: +91-98219-23797, E mail mira.desai@sunpharma.com
COPYRIGHT 2009 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2009 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire Europe
Date:Jan 7, 2009
Words:723
Previous Article:Global Mobile Operator Selects Epitiro for World's First Femtocell Pre-Deployment Analysis.
Next Article:Derek Simpson Joins Gordon Brown as the Prime Minister Visits Rolls Royce in Derby.
Topics:


Related Articles
Sun Pharma Gets USFDA Approval for Generic Fosamax (R) Tablets.
Sun Pharmaceutical Announces USFDA Approval to Market Generic Paraplatin(R) Injection.
Sun Pharma Continues Strong Performance.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters